Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1·36%^® and Dianeal PD1 3·86%^®).

Background and objective: Moxifloxacin is a new fluorquinolone with broad-spectrum activity. It is suitable for treating peritonitis in peritoneal dialysis (PD) patients. The objective of this study was to test stability of moxifloxacin in PD solutions stored at different temperatures. Methods: Dialysis solution bags were used at two glucose concentrations; Dianeal PD1 1·36%® and Dianeal PD1 3·86%®. Moxifloxacin solution (2%) was injected into nine 2-L bags of Dianeal PD1 1·36%® and nine bags of Dianeal PD1 3·86%® under aseptic conditions to achieve a nominal concentration of 25 mg/L. Three bags of Dianeal PD1 1·36%® and three bags of Dianeal PD1 3·86%® were stored at each of three temperatures (4, 25 and 37 °C) and the same way for. Duplicate samples (2 mL) were taken at different times and precipitation, cloudiness, colour and pH was analysed. Moxifloxacin concentrations were measured using a modified HPLC method. Results: The mean moxifloxacin concentration in the Dianeal PD1 1·36% solution remained ≥90% of the initial concentration for 14 days at 4 °C, 7 days at 25 °C and 3 days at 37 °C. For Dianeal PD1 3·86%® moxifloxacin concentrations remained ≥90% for 14 days at 4 °C, 3 days at 25 °C and 12 h at 37 °C. Conclusions: Moxifloxacin shows sufficient stability in both PD bags for use in PD patients. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Pharmacy & Therapeutics is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)